ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1939

Assessing The Increasing Costs To Manage Patients With Gout By State

Aaron Davis1 and Jason Wreath2, 12 calle guijarro, Goutchoices.com, San Clemente, CA, 2Symphony Health, Phoenix, AZ

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Cost containment, gout and prescribing trends

  • Tweet
  • Email
  • Print
Session Information

Title: ARHP Health Services Research

Session Type: Abstract Submissions (ARHP)

Background/Purpose:

Gout is a chronic progressive disease and worldwide prevalence is increasing. After over 40 years with limited and inexpensive treatments several new and more expensive treatment options are available. Although gout treatment guidelines are well established, variances in treatment patterns exist. The objective was to identify the rate of gout by state and estimate the budget impact of treating patients with chronic urate lowering and acute gout treatments. 

Methods:

Estimates from NHANES were used to project the rate of gout by state and compared to Symphony Health Solutions’ ProMetis longitudinal patient data. Symphony Health Solutions’ PHAST database provides destailed estimates of chronic and acute pharmaceutical treatments for gout.Looking at prevelance rates across states and treatment estimates between 2007 and 2012 costs by state by yearare estimated and presented in constant dollars using published wholesale acquisition costs for drugs. 

Results:

In 2011 gout is estimated to impact 9.2 million individuals based on NHANES estimates. Total gout pharmaceutical spend in the 2012 data was $1.038 billion, a 918% increase since 2007. Total number of prescriptions for gout rose 27% over the same time period. The costs of gout treatments vary: allopurinol at less than a dollar a day, febuxostat $2,250 per year; and pegloticase has the potential to cost as much as $100,000 per year. Acute and prophylaxic treatment colchicine now costs between $4.94 and $9.88 per day. Four states were identified accounting for approximately 30% of all pharmaceutical spending on gout; California, Florida, Texas and New York. Although colchicine does not treat the underlying urate burden found in patients with gout it accounted for over 55% of the total drug spend for patients with gout in in 2012; up from less than 20% in 2007. Among urate lowering therapies, febuxostat accounted for 60% of pharmaceutical costs, yet, allopurinol accounted for 93% of all fills across the U.S. State-by-state differences were seen in the utilization of urate lowering therapies, with higher colchicine prescribing leading to increased drug expenditure within certain states. Hawaii (1377%), South Carolina (1324%) and Georgia (1274%) have been most affected by increasing gout treatment costs, driven primarily by colchicine prescribing. 

Conclusion:

With an aging population and increasing rates of obesity, the rate of gout will continue to rise in the US. Recently launched drugs have increased the drug spend on gout. Forthcoming and likely expensive treatments will further add to the pharmaceutical budget impact of gout in the coming years. Reviewing treatment patterns within geographies will identify opportunities for gout education; including early identification, lifestyle management, treating the underlying cause of the disease vs. symptoms and utilization of effective generic medications. Early identification and treatment with effective generic medications will offer savings to the health care system. 


Disclosure:

A. Davis,
None;

J. Wreath,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/assessing-the-increasing-costs-to-manage-patients-with-gout-by-state/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology